Quick filters
- Incyte Reports Second Quarter 2011 Financial Results and Provides Update on Key Clinical Programs Business Wire | Thursday July 28, 2011 7:00AM
- Incyte Reports Second Quarter 2011 Financial Results and Provides Update on Key Clinical Programs on July 28 Business Wire | Wednesday July 13, 2011 4:15PM
- Incyte Reports Additional Analyses of Symptomatic Improvement and Quality of Life with Ruxolitinib (INC424) in Patients with Myelofibrosis from the COMFORT-I Study Business Wire | Saturday June 11, 2011 12:30PM
- Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration Business Wire | Monday June 6, 2011 8:00AM
- Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting Business Wire | Saturday June 4, 2011 2:30PM
- Incyte to Present at Upcoming Investor Conferences Business Wire | Tuesday May 24, 2011 4:15PM
- Incyte Reports First Quarter 2011 Financial Results and Program Updates Business Wire | Tuesday May 3, 2011 7:00AM
- Incyte to Present at the Bank of America Merrill Lynch Healthcare Conference Business Wire | Wednesday April 27, 2011 4:15PM
- Incyte to Report First Quarter 2011 Financial Results and Provide Update on Drug Discovery & Development Programs on May 3 Business Wire | Thursday April 14, 2011 4:15PM
- Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology Program Business Wire | Tuesday April 5, 2011 7:30AM
- Incyte's Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study Business Wire | Tuesday March 15, 2011 2:15AM
- Incyte to Present at the Cowen and Company 31st Annual Health Care Conference Business Wire | Wednesday February 23, 2011 4:15PM
- Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives and Financial Guidance Business Wire | Thursday February 10, 2011 7:00AM
- Incyte to Report 2010 Financial Results and Provide 2011 Key Objectives and Financial Guidance on February 10 Business Wire | Friday January 28, 2011 8:00AM
- Incyte to Present at the 29th Annual J.P. Morgan Healthcare Conference Business Wire | Monday January 3, 2011 4:15PM
- Incyte Announces Positive Top-Line Results from COMFORT-I Pivotal Phase III Trial of INCB18424 in Myelofibrosis, a Debilitating, Life-Threatening Blood Cancer Business Wire | Monday December 20, 2010 4:05PM
- Incyte Presents Positive Long-Term Results from Ongoing Phase II Trial of INCB18424 in Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) at the American Society of Hematology Annual Meeting Business Wire | Monday December 6, 2010 7:15AM
- Incyte to Present at the 22nd Annual Piper Jaffray Health Care Conference Business Wire | Thursday November 18, 2010 8:00AM
- Incyte's Selective Oral JAK1 and JAK2 Inhibitor Demonstrates Positive Phase IIa Results in Patients with Active Rheumatoid Arthritis Business Wire | Wednesday November 10, 2010 5:45PM
- Incyte to Host Webcast at 2010 ACR/ARHP Annual Scientific Meeting Business Wire | Wednesday November 10, 2010 11:57AM
Live Discussion of INCY on StockTwits